Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

Creatine supplementation could lead to a faster reduction in depressive symptoms compared to traditional antidepressants,' ...

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...

Psilocybin therapy significantly decreased moderate to severe symptoms of depression in clinicians after frontline work ...

Groundbreaking research shows psilocybin therapy equals traditional antidepressants in treating depression with potential ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

Innovative research to assess the effectiveness of digital and talking therapies for anxiety and depression has been given a ...

Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...

However, some believe ECT affects neurotransmitters, hormones, brain structure, and cell regeneration, contributing to an improvement in depression. Learn more about ECT. During shock therapy ...

Depression is not just a mental health issue it’s a condition that affects the entire body and can accelerate the onset of ...